These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23083859)

  • 1. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai SM
    J Urol; 2012 Dec; 188(6):2183-8. PubMed ID: 23083859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain on androgen deprivation therapy: which patients are at highest risk?
    Seible DM; Gu X; Hyatt AS; Beard CJ; Choueiri TK; Efstathiou JA; Miyamoto DT; Mitin T; Martin NE; Sweeney CJ; Trinh QD; Beckman JA; Basaria S; Nguyen PL
    Urology; 2014 Jun; 83(6):1316-21. PubMed ID: 24726149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai S
    Cancer; 2012 Apr; 118(7):1940-5. PubMed ID: 22009684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
    J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
    J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry.
    Cary KC; Singla N; Cowan JE; Carroll PR; Cooperberg MR
    J Urol; 2014 Apr; 191(4):964-70. PubMed ID: 24184370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.
    Gonzalez BD; Jim HS; Donovan KA; Small BJ; Sutton SK; Park J; Lin HY; Spiess PE; Fishman MN; Jacobsen PB
    J Urol; 2015 Sep; 194(3):690-5. PubMed ID: 25791402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
    Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
    J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer.
    Marzouk S; Naglie G; Tomlinson G; Duff Canning S; Breunis H; Timilshina N; Alibhai SMH
    J Urol; 2018 Aug; 200(2):327-334. PubMed ID: 29477720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.